Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 289

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 289
---
 clinical trials and in any event, is not using CSL’s fibrinogen.

From time to time, the Company has been
and may be in the future subject to other legal proceedings, claims, investigations, and government inquiries (collectively, “Legal
Proceedings”) in the ordinary course of business. There are no currently pending legal proceedings that the Company believes will
have a material adverse impact on the business or financial statements.

| NOTE 10:- | TEMPORARY EQUITY |

The preferred shares confer upon their
holders all rights accruing to holders of ordinary shares (as detailed below in this Note 10) in the Company, and, in addition, the rights,
preferences and privileges granted to the preferred shares as follows:

| A. | Dividends and Other Distributions |

The holders of all convertible preferred
shares shall be entitled to receive, when and if declared by the board of directors, a noncumulative dividend. Such dividends will be
distributed to the holders of the ordinary shares and the preferred shares on a pro-rata basis. No dividends have been declared to date.

Other distributions described in Company’s
AOA as follows: If the Company shall declare a distribution payable in securities of other persons, evidences of indebtedness issued by
the Company or other persons, assets (excluding cash dividends) or options or rights, or if the Company at any time shall pay a dividend
payable in additional ordinary shares or other securities or rights convertible into, or entitling the holder thereof to receive directly
or indirectly, additional ordinary shares, then, in each such case, the holders of preferred shares shall be entitled to receive such
distribution in respect of their holdings on an as-converted basis as of the record date for such distribution.

| B. | Conversion Rights |

Each preferred share shall be convertible,
at the option of the holder thereof, into such number of fully paid and non-assessable ordinary shares of the Company at a 1:1 ratio,
subject to certain adjustment such as splits and combinations, recapitalization, adjustments for dividend or other distribution as fully
described in Company’s AOA.

| C. | Automatic and Mandatory Conversion |

Each preferred share shall
automatically be converted without payment of additional consideration into ordinary shares at the conversion rate (as described
above) then in effect: (i) immediately prior to the closing of a QIPO (means the closing of an IPO at a pre-money equity valuation
of the Company of at least US $120